Gaurav Sutrave
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gaurav Sutrave has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- David Jonathan Gottlieb
Faculty of Medicine and Health The University of Sydney Camperdown New South Wales Australia
3 shared publications - Emily Blyth
Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, NSW, Australia
2 shared publications - Michelle K. Yong
Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia
2 shared publications Alla Dolnikov
Children's Cancer Institute, University of New South Wales, Sydney, NSW, Australia
1 shared publicationAllison Abendroth
Infection, Immunity, and Inflammation School of Medical Sciences Faculty of Medicine and Health The University of Sydney Sydney New South Wales Australia
1 shared publication- Andrea S. Henden
Department of Haematology and Bone Marrow Transplantation Cancer Care Services, Royal Brisbane and Women's Hospital Brisbane Queensland Australia
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by Elsevier in Molecular Therapy Oncology
Novel TCR-T cells targeting WT137-45 demonstrating anti-cancer reactivity
- 6 November 2026
- Published by Elsevier in Molecular Therapy Oncology
Open AccessNovel TCR-T cells targeting WT137-45 demonstrating anti-cancer reactivity
- Open Access
- 10 September 2026
- Published by Wiley in Internal Medicine Journal
ANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand
Background: Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. Aims and Methods: To understand the state of practice in Australia, a survey captured insights on detection, monitoring, prophylaxis and treatment from 21 sites, including 11 chimeric antigen receptor T‐cell (CAR‐T) therapy sites. Results: Respondents reported 26 cases of CMV disease after HSCT and four cases after CAR‐T in 2024. All HSCT sites and four CAR‐T sites had CMV protocols. Commonly, CMV nucleic acid viral load (VL) testing was employed weekly. Sites utilised plasma (66%) or whole blood (33%). VL was reported as IU/mL (66%), copies/mL (29%) or not specified (5%). One third of respondents tested CMV DNAemia before HSCT. All recipients were monitored regardless of CMV serostatus. Half the sites employed post‐HSCT CMV prophylaxis using letermovir (nine sites), (val)aciclovir (eight) and (val)ganciclovir (three). VL thresholds for PeT ranged from 100 to 5000 IU/mL. Most sites used (val)ganciclovir for PeT, with foscarnet second line. At 76% of HSCT sites, PeT continued until two consecutive negative results. Frontline therapy for CMV disease is ganciclovir; 86% of ANZ sites used (val)ganciclovir while three paediatric sites used foscarnet. For resistant or refractory CMV, guidelines recommend foscarnet or maribavir, although maribavir was not funded or used during the survey period. CMV‐specific immunotherapy can be considered. Conclusions: Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines.
- 10 September 2026
- Published by Wiley in Internal Medicine Journal
Open AccessANZTCT cytomegalovirus practice survey for allogeneic haemopoietic stem cell transplant and cellular therapy recipients in Australia and New Zealand
Background: Despite pre‐emptive treatment (PeT), cytomegalovirus (CMV) disease and reactivation remain a clinical concern. In Australia and New Zealand (ANZ), variability exists in the management of CMV for haematopoietic stem cell transplantation (HSCT) recipients. Aims and Methods: To understand the state of practice in Australia, a survey captured insights on detection, monitoring, prophylaxis and treatment from 21 sites, including 11 chimeric antigen receptor T‐cell (CAR‐T) therapy sites. Results: Respondents reported 26 cases of CMV disease after HSCT and four cases after CAR‐T in 2024. All HSCT sites and four CAR‐T sites had CMV protocols. Commonly, CMV nucleic acid viral load (VL) testing was employed weekly. Sites utilised plasma (66%) or whole blood (33%). VL was reported as IU/mL (66%), copies/mL (29%) or not specified (5%). One third of respondents tested CMV DNAemia before HSCT. All recipients were monitored regardless of CMV serostatus. Half the sites employed post‐HSCT CMV prophylaxis using letermovir (nine sites), (val)aciclovir (eight) and (val)ganciclovir (three). VL thresholds for PeT ranged from 100 to 5000 IU/mL. Most sites used (val)ganciclovir for PeT, with foscarnet second line. At 76% of HSCT sites, PeT continued until two consecutive negative results. Frontline therapy for CMV disease is ganciclovir; 86% of ANZ sites used (val)ganciclovir while three paediatric sites used foscarnet. For resistant or refractory CMV, guidelines recommend foscarnet or maribavir, although maribavir was not funded or used during the survey period. CMV‐specific immunotherapy can be considered. Conclusions: Institutional preferences and medicine funding drives variability in ANZ practice. This leaves potential for healthcare inequity since newer antiviral agents are inconsistently used, contrasting with international guidelines.
- Open Access
- 14 April 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (3) , e70142
Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response
Human cytomegalovirus (HCMV) is one of the most important opportunistic pathogens in immunocompromised individuals, including allogeneic haematopoietic stem cell transplant (allo‐HSCT) recipients. In allo‐HSCT, HCMV seropositivity of the recipient and donor is associated with inferior survival outcomes, and post‐transplant HCMV reactivation is a frequent complication, necessitating close viral monitoring and pre‐emptive and prophylactic antiviral therapies. We present a review in two parts that focuses on the risk factors, immunological responses and treatment strategies for HCMV infection in allo‐HSCT recipients, and also explores current evidence surrounding HCMV reactivation in recipients of chimeric antigen receptor T cell (CAR T) therapies. In the current article (Part 1), the impact of HCMV infection in allo‐HSCT and CAR T cell recipients is investigated. HCMV reactivation in allo‐HSCT recipients is associated with increased mortality, graft‐versus‐host disease (GvHD) and other microbial infections. Prominent alterations in T cell and natural killer (NK) cell recovery represent distinct immune reconstitution features associated with HCMV reactivation. Immunological biomarkers to predict HCMV complications have been proposed and their adoption in future immune monitoring strategies may allow individualised risk assessment to guide antiviral treatment decisions. The clinical significance of HCMV reactivation after CAR T cell infusion is yet to be fully determined. Continued viral surveillance and investigation of viral dynamics with correlative studies of immune function are needed in this patient population. Current and emerging strategies for treatment and prevention of HCMV complications in allo‐HSCT, including use of letermovir prophylaxis and adoptive HCMV‐specific T cell therapies, are explored in the following article (Part 2).
- 14 April 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (3) , e70142
Open AccessHuman Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response
Human cytomegalovirus (HCMV) is one of the most important opportunistic pathogens in immunocompromised individuals, including allogeneic haematopoietic stem cell transplant (allo‐HSCT) recipients. In allo‐HSCT, HCMV seropositivity of the recipient and donor is associated with inferior survival outcomes, and post‐transplant HCMV reactivation is a frequent complication, necessitating close viral monitoring and pre‐emptive and prophylactic antiviral therapies. We present a review in two parts that focuses on the risk factors, immunological responses and treatment strategies for HCMV infection in allo‐HSCT recipients, and also explores current evidence surrounding HCMV reactivation in recipients of chimeric antigen receptor T cell (CAR T) therapies. In the current article (Part 1), the impact of HCMV infection in allo‐HSCT and CAR T cell recipients is investigated. HCMV reactivation in allo‐HSCT recipients is associated with increased mortality, graft‐versus‐host disease (GvHD) and other microbial infections. Prominent alterations in T cell and natural killer (NK) cell recovery represent distinct immune reconstitution features associated with HCMV reactivation. Immunological biomarkers to predict HCMV complications have been proposed and their adoption in future immune monitoring strategies may allow individualised risk assessment to guide antiviral treatment decisions. The clinical significance of HCMV reactivation after CAR T cell infusion is yet to be fully determined. Continued viral surveillance and investigation of viral dynamics with correlative studies of immune function are needed in this patient population. Current and emerging strategies for treatment and prevention of HCMV complications in allo‐HSCT, including use of letermovir prophylaxis and adoptive HCMV‐specific T cell therapies, are explored in the following article (Part 2).
- 30 March 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (8) , 842-857
Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers
- 30 March 2024
- Published by Elsevier in Cytotherapy
- Vol. 26 (8) , 842-857
Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers
- 10 March 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (6) , 590-597
Early Stage Professionals Committee proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting
- 10 March 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (6) , 590-597
Early Stage Professionals Committee proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting
- Open Access
- 22 March 2022
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 25, 250-263
Characterizing piggyBat—a transposase for genetic modification of T cells
- 22 March 2022
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 25, 250-263
Open AccessCharacterizing piggyBat—a transposase for genetic modification of T cells
- Open Access
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2825
Third-Party Partially HLA Matched Fungus-Specific T-Cells (FSTs) Used to Treat Invasive Fungal Infection (IFI) with Scedosporium Aurantiacum after Allogeneic Hemopoietic Stem Cell Transplant (aHSCT)
Introduction Invasive fungal infection (IFI) is a potentially devastating complication after allogeneic stem cell transplantation (aHSCT). Breakthrough infections are an increasing threat. The adoptive transfer of fungus-specific T cells (FSTs), analogous to virus specific T-cells for viral reactivation, may improve clinical outcomes but the delay involved in generating FSTs from the stem cell donor is problematic for this type of adoptive cell therapy. We created a bank of FSTs from normal donors for use in patients with post-transplant IFI. Here we describe the first use of partially HLA matched 3 rd party FSTs to treat IFI in a patient after aHSCT. Methods FSTs were manufactured by stimulating G-CSF primed apheresis products overnight with monocyte derived dendritic cells pulsed with lysates from Aspergillus terreus and Candida krusei. CD137 expressing cells were isolated and cultured with CD137 negative feeders in medium supplemented with IL-2, IL-7 and IL-15 for 12 days prior to assessment of target specificity and HLA restriction. Cells consisted principally of CD4 + lymphocytes secreting TNF-α, interferon-γ and IL-17 in response to fungal antigen stimulation. Standard release criteria were applied. We commenced a phase 1 cell dose escalation trial to assess the safety and efficacy of partially HLA-DR matched 3 rd party FSTs from a cryopreserved bank in patients with proven or probable IFI after aHSCT. Results Patient A is a 27 year old female who underwent a myeloablative sibling haploidentical transplant for Philadelphia negative B-ALL in second remission. At day 100 she developed grade III lower GI GVHD requiring methylprednisolone and ruxolitinib for steroid dependent disease. Subsequent CMV reactivation was treated with ganciclovir. Cough in association with pulmonary infiltrates followed, and a bronchoalveolar lavage grew Scedosporium aurantiacum, Clavispora lusitaniaand Aspergillus fumigatus. She developed severe headache and MRI imaging showed a thin rim-enhancing 38x37 mm lesion within the right frontal lobe with moderate vasogenic oedema. Surgical drainage yielded 20 ml of frank pus that grew Scedosporium aurantiacum. Antifungal therapy was started with vorinconazole, terbinafine, amphotericin and later caspofungin. Serial imaging after 12 days showed two new hyperdense foci representing extension of infection, consistent with worsening headaches. The patient received a single infusion of 3 rd party FSTs at a dose of 1 x10 6/m 2 at day 170 post-transplant while continuing antifungal therapy with vorinconazole and terbinafine. The product consisted of 94.1% CD4 +, 3.5% CD8 + T-cells and 1% NK cells and contained CD4 + T-cells responsive to both A. terreus and C. krusei antigens presented by HLA DR*03:01 shared between product and patient. There were no infusion related adverse events. Corticosteroids and calcineurin inhibitors were continued. Within one week of FST infusion there was an increase in the number of naïve and central memory CD4 + T-cells in blood and a fall in the number of CD4 + and CD8 + T-cells expressing Tim3. Over the following 3 months, there was a gradual rise in the number of CD4 + Tem and CD4 + Temra with a later and less pronounced rise in the analogous CD8 + populations. Serial imaging demonstrated rapid regression of the pulmonary abnormalities and gradual regression of the cerebral lesion at day 150 following FST infusion. 279 days after transplant and 109 days after infusion of FSTs, the patient developed worsening of headache and MRI confirmed rupture of the abscess into the right ventricle. Headache gradually resolved and the patient was discharged from hospital 329 days after transplant with ECOG 1 and no neurological abnormalities. However she was readmitted 13 days later with more severe headache with repeat imaging confirming raised intracranial pressure. CSF showed no evidence of fungi by PCR or culture. A CSF shunt was inserted and the patient remains well. Conclusion We report the first infusion of 3 rd party partially HLA DR matched fungus-specific T-cells for disseminated fungal infection following allogeneic stem cell transplantation. These data demonstrate the feasibility of this approach. The patient's favourable clinical outcome and phenotyping results suggest that the initial cell dose level is safe and may be associated with immune alterations that promote anti-fungal activity. Further trial recruitment is ongoing.
- 5 November 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (Supplement) , 2825
Open AccessThird-Party Partially HLA Matched Fungus-Specific T-Cells (FSTs) Used to Treat Invasive Fungal Infection (IFI) with Scedosporium Aurantiacum after Allogeneic Hemopoietic Stem Cell Transplant (aHSCT)
Introduction Invasive fungal infection (IFI) is a potentially devastating complication after allogeneic stem cell transplantation (aHSCT). Breakthrough infections are an increasing threat. The adoptive transfer of fungus-specific T cells (FSTs), analogous to virus specific T-cells for viral reactivation, may improve clinical outcomes but the delay involved in generating FSTs from the stem cell donor is problematic for this type of adoptive cell therapy. We created a bank of FSTs from normal donors for use in patients with post-transplant IFI. Here we describe the first use of partially HLA matched 3 rd party FSTs to treat IFI in a patient after aHSCT. Methods FSTs were manufactured by stimulating G-CSF primed apheresis products overnight with monocyte derived dendritic cells pulsed with lysates from Aspergillus terreus and Candida krusei. CD137 expressing cells were isolated and cultured with CD137 negative feeders in medium supplemented with IL-2, IL-7 and IL-15 for 12 days prior to assessment of target specificity and HLA restriction. Cells consisted principally of CD4 + lymphocytes secreting TNF-α, interferon-γ and IL-17 in response to fungal antigen stimulation. Standard release criteria were applied. We commenced a phase 1 cell dose escalation trial to assess the safety and efficacy of partially HLA-DR matched 3 rd party FSTs from a cryopreserved bank in patients with proven or probable IFI after aHSCT. Results Patient A is a 27 year old female who underwent a myeloablative sibling haploidentical transplant for Philadelphia negative B-ALL in second remission. At day 100 she developed grade III lower GI GVHD requiring methylprednisolone and ruxolitinib for steroid dependent disease. Subsequent CMV reactivation was treated with ganciclovir. Cough in association with pulmonary infiltrates followed, and a bronchoalveolar lavage grew Scedosporium aurantiacum, Clavispora lusitaniaand Aspergillus fumigatus. She developed severe headache and MRI imaging showed a thin rim-enhancing 38x37 mm lesion within the right frontal lobe with moderate vasogenic oedema. Surgical drainage yielded 20 ml of frank pus that grew Scedosporium aurantiacum. Antifungal therapy was started with vorinconazole, terbinafine, amphotericin and later caspofungin. Serial imaging after 12 days showed two new hyperdense foci representing extension of infection, consistent with worsening headaches. The patient received a single infusion of 3 rd party FSTs at a dose of 1 x10 6/m 2 at day 170 post-transplant while continuing antifungal therapy with vorinconazole and terbinafine. The product consisted of 94.1% CD4 +, 3.5% CD8 + T-cells and 1% NK cells and contained CD4 + T-cells responsive to both A. terreus and C. krusei antigens presented by HLA DR*03:01 shared between product and patient. There were no infusion related adverse events. Corticosteroids and calcineurin inhibitors were continued. Within one week of FST infusion there was an increase in the number of naïve and central memory CD4 + T-cells in blood and a fall in the number of CD4 + and CD8 + T-cells expressing Tim3. Over the following 3 months, there was a gradual rise in the number of CD4 + Tem and CD4 + Temra with a later and less pronounced rise in the analogous CD8 + populations. Serial imaging demonstrated rapid regression of the pulmonary abnormalities and gradual regression of the cerebral lesion at day 150 following FST infusion. 279 days after transplant and 109 days after infusion of FSTs, the patient developed worsening of headache and MRI confirmed rupture of the abscess into the right ventricle. Headache gradually resolved and the patient was discharged from hospital 329 days after transplant with ECOG 1 and no neurological abnormalities. However she was readmitted 13 days later with more severe headache with repeat imaging confirming raised intracranial pressure. CSF showed no evidence of fungi by PCR or culture. A CSF shunt was inserted and the patient remains well. Conclusion We report the first infusion of 3 rd party partially HLA DR matched fungus-specific T-cells for disseminated fungal infection following allogeneic stem cell transplantation. These data demonstrate the feasibility of this approach. The patient's favourable clinical outcome and phenotyping results suggest that the initial cell dose level is safe and may be associated with immune alterations that promote anti-fungal activity. Further trial recruitment is ongoing.